Metabolic syndrome after transplantation is a major concern following solid organ transplantation (SOT). The CREB-regulated transcription co-activator 2 (CRTC2) regulates glucose metabolism. The effect of CRTC2 polymorphisms on new-onset diabetes after transplantation (NODAT) was investigated in a discovery sample of SOT recipients (n 1 = 197). Positive results were tested for replication in two samples from the Swiss Transplant Cohort Study (STCS, n 2 = 1294 and n 3 = 759). Obesity and other metabolic traits were also tested. Associations with metabolic traits in population-based samples (n 4 = 46'186, n 5 = 123'865, n 6 4100,000) were finally analyzed. In the discovery sample, CRTC2 rs8450-AA genotype was associated with NODAT, fasting blood glucose and body mass index (P corrected o0.05). CRTC2 rs8450-AA genotype was associated with NODAT in the second STCS replication sample (odd ratio (OR) = 2.01, P = 0.04). In the combined STCS replication samples, the effect of rs8450-AA genotype on NODAT was observed in patients having received SOT from a deceased donor and treated with tacrolimus (n = 395, OR = 2.08, P = 0.02) and in non-kidney transplant recipients (OR = 2.09, P = 0.02). Moreover, rs8450-AA genotype was associated with overweight or obesity (n = 1215, OR = 1.56, P = 0.02), new-onset hyperlipidemia (n = 1007, OR = 1.76, P = 0.007), and lower high-density lipoprotein-cholesterol (n = 1214, β = -0.08, P = 0.001). In the population-based samples, a proxy of rs8450G4A was significantly associated with several metabolic abnormalities. CRTC2 rs8450G4A appears to have an important role in the high prevalence of metabolic traits observed in patients with SOT. A weak association with metabolic traits was also observed in the population-based samples.
INTRODUCTION
The introduction of calcineurin inhibitors-cyclosporine and tacrolimus (TAC)-in solid organ transplantation (SOT) has reduced the incidence of acute rejection episodes and improved short-term graft survival. 1, 2 However, both drugs are not devoid of metabolic complications, such as glucose intolerance, hypertension and hyperlipidemia, which can be very pronounced and have a detrimental impact on patients' life quality, and increase the mortality risk owing to cardiovascular events. 3 Indeed, cardiovascular disease is responsible for~20-40% of non-graftrelated death after the first post transplantation year. [4] [5] [6] New-onset diabetes mellitus after transplantation (NODAT) is a serious complication partly related to the use of calcineurin inhibitors, mainly TAC. 7, 8 It is also associated with increased cardiovascular events, infectious complications and graft loss. 9, 10 There are several risk factors, which increase the risk of NODAT in transplantation such as obesity, increased age, male sex, deceased donor, hepatitis C status, acute rejection and African-American or Hispanic descent. 9, 11 The identification of genetic factors involved in the development of NODAT may greatly benefit from a more detailed understanding of the complex metabolic pathways involved in glucose metabolism. Genome-wide association studies (GWAS) conducted to date explain only 10% of type 2 diabetes heritability and more diabetic susceptibility genes remain to be discovered (reviewed in 12 and 13 ) . A recent GWAS investigating NODAT identified eight polymorphisms. 14 However, only one of these was replicated in another study. 15 Whereas GWAS have been extremely valuable, other approaches are needed to further understand the pathophysiology of NODAT.
The CREB-regulated transcriptional co-activator 2 (CRTC2), a transcriptional co-activator that promotes the transcription of genes targeted by the cAMP response element-binding protein, CRTC1 polymorphisms and obesity markers (body mass index (BMI) and fat mass) in psychiatric and population-based samples, 18 CRTC2 is highly expressed in the thymus, and present in both T-and B-lymphocytes. 17 It is also expressed in the liver and it has a direct role during the fasting state in the induction of gluconeogenic genes. 16 It further enhances the hepatic insulin signaling by stimulating expression of the insulin receptor substrate 2 gene, thus triggering a feedback response that limits glucose output from the liver during fasting, 19 Calcineurin, the target of both TAC and cyclosporine, has an important role in the activation of CRTC2. 20, 21 Overexpression of CRTC2 induced by a mutation at 2 regulatory sites rendered CRTC2 constitutively active in an animal model and permitted CRTC2-target gene activation even when calcineurin was inhibited by calcineurin inhibitors. 22 The authors of this study also showed that CRTC2 is required for β-cell function and proliferation and promoting this pathway could ameliorate symptoms of NODAT.
22
CRTC2 single-nucleotide polymorphisms (SNPs) were previously investigated in two Asian populations and one coding SNP (R379C), with a very low minor allele frequency (MAF), was associated with type II diabetes 23 and with lung cancer. 24 So far CRTC2 SNPs have not been investigated in other ethnic populations or with other phenotypes. In this work, we aimed to study the influence of CRTC2 SNPs on the incidence of NODAT in a sample of Caucasian SOT recipients, and positive results were then tested for replication in the Swiss Transplant Cohort Study (STCS). We also aimed to extend our analysis to obesity and other variables of the metabolic syndrome (MetS) following SOT. Finally, we aimed to test whether the associations with MetS components could be found in general population-based samples (4100,000 subjects).
MATERIALS AND METHODS

Discovery study sample
This study aimed initially to investigate the effect of genetic polymorphisms of drug metabolizing enzymes and/or transporters on the incidence of different post transplant complications and on immunosuppressive doses and blood levels. 25, 26 For this study, a total of 197 patients were enrolled between 2003 and 2005 from the outpatient clinic of the Transplant Center of the University Hospital of Lausanne, Switzerland. Patients with functional graft for 412 months after transplantation were eligible to participate in the study. Data regarding patient's age, gender, BMI, ethnic origin, donor's age, HLA mismatch, duration of graft cold ischemia and delayed graft function were collected retrospectively from patients' medical files. Immunosuppressive regimens, doses and blood levels were obtained retrospectively at different time points during the first year post transplantation. The study was approved by the ethics committee of the University of Lausanne. Patients gave their written informed consent to participate in this pharmacogenetic study. Once included, venous blood samples were collected for DNA extraction and further genotyping analysis.
For the present study, data were collected between October 2011 and April 2012 as related to the development of NODAT during the first 5 years following transplantation. Data regarding fasting blood glucose (FBG), glycated haemoglobin (HbA1c), 2 h oral glucose tolerance test, insulin and oral anti-diabetic treatment were collected retrospectively from the medical files at the time of transplantation, at 1, 3, 6, 9 and 12 month post transplantation and at the yearly follow-up until 5-year post transplantation. NODAT was diagnosed if a patient needed anti-diabetic treatment (either insulin or oral anti-diabetic agents) for at least 6 months following transplantation or had several abnormal glucose profiles during the follow-up period that fulfill the criteria given by the WHO and ADA consensuses, 27 including FBG ⩾ 7.0 mmol l − 1 (in ⩾ 2 occasions) or 2 h plasma glucose ⩾ 11.1 mmol l − 1 during oral glucose tolerance test 27 (even if not treated with anti-diabetic drugs). Patients who had diabetes or prediabetes before transplantation or were transplanted because of diabetic nephropathy were excluded from the present study.
The Swiss Transplant Cohort Study
The STCS is an ongoing prospective multicenter cohort project (Basel, Bern, Genève, Lausanne, St. Gallen and Zurich), aiming at a nationwide comprehensive and structured data collection in all SOT recipients. All recipients of SOTs in Switzerland are prospectively registered since May 2008. Currently 43500 patients are included in the STCS. No particular eligibility or exclusion criteria exist for enrollment. After transplantation, all patients are mandatorily followed in their respective transplant centers. After baseline assessment, STCS follow-up assessments take place at 6-, 12 months and yearly thereafter. Biological samples are collected in relation to the case at baseline, and at 6-, and 12-month visits. Data regarding patient's age, gender, BMI, blood pressure and lipid profiles (total cholesterol, high-density lipoprotein (HDL)-and low-density lipoprotein (LDL)-cholesterol) were available for all patients at the different time points of the STCS follow-up. Full description of this cohort is published elsewhere. 28, 29 For the first STCS replication sample, patients transplanted from May 2008 to 8 May 2011 with a functional graft for at least 12 months after transplantation were included in the analyses (n = 1294). NODAT was diagnosed if a patient needed anti-diabetic treatments following transplantation or if such new metabolic event was reported in their case report forms. For the second STCS replication sample, patients transplanted from 9 May 2011 to May 2013 with a functional graft for at least 12 months after transplantation were included in the analyses (n = 759). For this second STCS replication sample, several random and FBG were available in the database as well as HbA1c. Therefore, as for the discovery sample, NODAT was diagnosed if a patient needed anti-diabetic treatment (either insulin or oral anti-diabetic agents) or fulfilled the criteria given by the WHO and ADA consensuses mentioned earlier. For both STCS samples, patients who were diagnosed with diabetes or were prediabetics before transplantation or were transplanted because of diabetic nephropathy were excluded from the NODAT analyses.
For the combined STCS sample, new-onset hypertension and new-onset hyperlipidemia were diagnosed if patients needed anti-hypertensive and hypolipidemic treatment post SOT. Patients with previous hypertension or hyperlipidemia were excluded from the new-onset hypertension and new-onset hyperlipidemia analyses, respectively. The study was approved by the ethics committee of their respective centers. Patients gave their written informed consent to participate in this pharmacogenetic study.
Recipients younger than 18 years old and recipients with multiple organ transplantation were excluded from the whole analyses. If a patient received more than one transplantation during the inclusion period, only data from the first SOT was included in the analyses.
For both the discovery and STCS samples, as abdominal obesity (waist circumference) was not available, BMI was used as a marker of obesity.
Population-based samples
We aimed to replicate results with MetS traits in several population-based samples: the Meta-Analyses Of Glucose and Insulin-related traits Consortium (MAGIC; n = 46,186). 30 Genetic Investigation of ANthropometric Traits (GIANT) consortium (n = 123,865), [31] [32] [33] and Genome-Wide Associations Scans for Total Cholesterol, HDL-C, LDL-C and triglycerides (n4100,000). 34, 35 More details are in the Supplementary Material.
Polymorphism selection and genotyping
Two tagging SNPs within CRTC2 gene (rs8450G4A and rs12117078G4C) were selected using HapMap Genome Browser by limiting the search to SNPs with a MAF45% in the Caucasian population and r 2 cutoff of 0.8. Genotyping in the discovery study sample was done using Taqman allelic discrimination assays. Genetic analyses for the STCS replication samples were done using the fluorescence-based competitive allele-specific PCR technology (KASPar). 36 More details are in the Supplementary Material.
Statistical analysis
Detailed statistical methods are presented in the Supplementary Material.
Discovery and STCS samples. We assessed the association of CRTC2 SNPs with MetS traits (1) by applying a logistic regression for binary outcomes adjusted for recipient's age at transplantation and sex. Other variables identified through the univariate analysis (Po 0.10) were also added as covariates in these models, (2) by using linear mixed models for continuous variables and (3) by fitting a Generalized Additive Mixed Model to include a smooth trend for the response in time (allowing multiple observations for each patient) for non-linear continuous variables (BMI and FBG).
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For the discovery sample, the P-values of the models were adjusted for multiple comparisons using Bonferroni correction and the SNP that survived this correction was investigated in the STCS.
Data for both the discovery and replications samples were analyzed using Stata 12 (StataCorp, College Station, TX, USA) and R version 2.13.0 software (http://www.R-project.org).
Population-based samples. We analyzed the associations of CRTC2 SNP with different MetS traits using multivariate linear regression with allele dosage in which potential confounding factors such as age, sex and smoking status were added as covariates.
RESULTS
Discovery and STCS replication samples
General characteristics of the discovery and STCS replication samples are presented in the Supplementary Material and Supplementary Tables 1 and 2. Supplementary Table 2 represents the global STCS sample without the exclusion of patients with previous history of diabetes or other metabolic abnormalities before transplantation.
The distribution of CRTC2 genotypes in all studies did not deviate from the Hardy-Weinberg equilibrium (P40.05) and the MAFs were similar to those reported in HapMap (Supplementary Table 3 ).
CRTC2 SNPs and NODAT, FBG and BMI in the discovery study sample Carriers of the CRTC2 rs8450-AA genotype showed increased risk of NODAT as compared with wild-type GG genotype (odd ratio (OR) = 6.91, 95% confidence interval (CI): 1.52-31.36, P corrected = 0.02). An increased risk was also observed by analyzing the rs8450 SNP in a recessive model (Table 1) . Neither cumulative prednisone dosages nor calcineurin inhibitors' doses, trough levels or concentration/dose ratios tested at 2 time periods (at 1 month or at 12 months post SOT) were associated with NODAT in the univariate analysis or when used in the multivariate model, including CRTC2 SNPs and the other covariables (data not shown).
FBG were also available at several time points after SOT. By applying the Generalized Additive Mixed Model model, increased FBG levels were found in patients with the CRTC2 rs8450-GA and AA genotypes (0.24 mmol l − 1 , P corrected = 0.06 and 0.47 mmol l − 1 , P corrected = 0.02, respectively) as compared with wild-type GG genotype. We observed an equal increased of FBG levels by analyzing the rs8450 SNP in dominant model (Table 1) .
Patients with the CRTC2 rs8450-GA genotype showed a 1.36 kg m − 2 increased BMI compared with the wild-type genotype (P corrected = 0.02). By analyzing the SNP in a dominant model, we observed a significant association between CRTC2 rs8450 and BMI (β = 1.17, 95% CI: 0.17-2.35, P corrected = 0.04).
We observed no association between CRTC2 rs12117078G4C SNP and NODAT, FBG or BMI (Table 1) .
CRTC2 SNP in the STCS replication samples The CRTC2 rs8450G4A SNP that survived corrections for multiple testing in the discovery study sample was investigated in the STCS. Recessive models for this SNP are presented in the text and in Tables 2 and 3 , while additive and dominant models regarding NODAT are presented in Supplementary Table 4 .
CRTC2 SNP and NODAT In the univariate analyses, increased recipient's age (P = 0.0003), male sex (P = 0.03), positive hepatitis C status (P = 0.003), deceased donor (P = 0.04), treatment with TAC (P = 0.001) and baseline BMI (P = 0.0002) were among the non-genetic factors associated with an increased risk of NODAT and were used as covariates in the genetic models. In the first STCS replication samples, we observed a non-significant association between rs8450G4A and NODAT (Table 2) . However, by analyzing the SNP in the subgroup of patients having received SOT from a deceased donor and treated with TAC, a significant effect of the SNP was observed (n = 281, OR = 2.36, 95% CI: 1.16-4.78, P = 0.01)( Table 2 ). In the second replication sample (n = 438), in which the diagnostic criteria for NODAT was the same as for the discovery sample, recipients carrying the rs8450-AA genotype showed a significant increased risk of NODAT (n = 438, OR = 2.01, 95% CI:1.03-3.91, P = 0.04). In the combined STCS sample, the effect of the CRTC2 genotype was only observed in the subgroup of patients having received SOT from a deceased donor and treated with TAC (n = 395, OR = 2.08, 95% CI: 1.15-3.74, P = 0.02) ( Table 2) .
CRTC2 SNP and BMI, new-onset hypertension/hyperlipidemia
We investigated the influence of CRTC2 rs8450G4A on BMI and on the incidence of new-onset hypertension/hyperlipidemia in the combined STCS sample. Abbreviations: BMI, body mass index; CI, confidence interval; CRTC2, CREB-regulated transcription co-activator 2; FBG, fasting blood glucose; NODAT, newonset diabetes after transplantation, OR, odd ratio; SNP, single-nucleotide polymorphism. Regarding NODAT and blood glucose levels analyses: P-values were adjusted for age of recipient at transplantation, sex of the recipient and baseline BMI and type of calcineurin inhibitor. Regarding BMI analyses: P-values were adjusted for age of recipient at transplantation, sex of the recipient and type of calcineurin inhibitor.
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Increased recipient's age (P o 0.0001), male sex (Po 0.0001) and type of transplanted organ (P o 0.0001) were among the non-genetic factors associated with increased BMI in the univariate analyses and were used as covariates in the genetic models. BMI values were also dichotomized into normal versus overweight or obese (BMI ⩾ 25 kg m − 2 ). At 12 months post SOT, overweight or obese patients were more prevalent in the CRTC2 rs8450-AA genotype compared with the other genotypes (n = 1215, OR = 1.56, 95% CI: 1.08-2.25, P = 0.02). We observed the same association but with lower significance for the combined STCS sample at 6 months post SOT (n = 1389, OR = 1.41, 95% CI: 1.01-1.97, P = 0.04), and a non-significant association with baseline BMI (n = 1515, OR = 1.20, 95% CI: 0.87-1.65, P = 0.27), suggesting that time post SOT modulates the effect of the CRTC2 genotypes.
By applying the Generalized Additive Mixed Model model to test the association between BMI over time and CRTC2 rs8450G4A SNP (n = 1625), patients with the CRTC2 rs8450-AA genotype showed a 0.47 kg m -2 (95% CI: 0.11-1.02, P = 0.01) increase in BMI compared with the other genotypes.
We found no association between the CRTC2 rs8450G4A and the incidence of new-onset hypertension (Supplementary Material). On the other hand, carriers of the CRTC2 rs8450-AA genotype showed increased risk of new-onset hyperlipidemia as compared with the other genotypes (n = 1007, OR = 1.76, 95% CI: 1.16-2.66, P = 0.007). In addition, patients with the CRTC2 rs8450-AA genotype also showed a significant decrease of HDL-cholesterol levels in the combined STCS sample (n = 1214, β = − 0.08 mmol l − 1 , P = 0.001). CRTC2 rs8540G4A SNP was not associated with total cholesterol or with LDL-cholesterol blood levels in the combined STCS sample (data not shown). More details can be found in the Supplementary Material.
CRTC2 SNP and MetS traits in kidney and non-kidney transplant recipients
Patients were dichotomized into kidney versus non-kidney transplant recipients (Table 3 ). The CRTC2 rs8450-AA genotype was associated with significantly higher OR for NODAT in nonkidney transplant recipients (n = 409, OR = 2.09, 95% CI: 1.13-3.86, P = 0.02), whereas the rs8450-AA genotype was only associated with higher risk of new-onset hyperlipidemia in kidney transplant recipients (n = 573, OR = 1.95, 95% CI: 1.14-3.15, P = 0.01).
Population-based samples Several glycemic traits were available in the MAGIC study (Supplementary Table 5) ; each rs1572788 C-allele (in complete Abbreviations: BMI, body mass index; CI, confidence interval; CRTC2, CREB-regulated transcription co-activator 2; FBG, Fasting blood glucose; MetS, metabolic syndrome; NODAT, new-onset diabetes after transplantation, OR, odd ratio; SNP, single-nucleotide polymorphism; SOT, solid organ transplantation; STCS, Swiss Transplant Cohort Study; TAC, tacrolimus. For NODAT analyses: P-values were adjusted for age of recipient at transplantation, sex of the recipient, baseline BMI, type of calcineurin inhibitor and type of donor. For BMI analyses: P-values were adjusted for age of recipient at transplantation and sex of the recipient. For new-onset hyperlipidemia analyses: P-values were adjusted for age of recipient at transplantation, sex of the recipient, baseline BMI, the type of calcineurin inhibitor and treatment with corticosteroids. For new-onset hypertension analyses: P-values were adjusted for age of recipient at transplantation and sex of the recipient, treatment with corticosteroids, the type of calcineurin inhibitor and type of donor.
CRTC2 and post-transplant metabolic syndrome L Quteineh et al linkage disequilibrium with rs8450 A-allele) increased FBG levels by 0.01 mmol l − 1 (n = 46,186, P = 0.004). In addition, each rs1572788 C-allele decreased HOMA-B by 0.008% (n = 46,186, P = 0.03). No association was observed between rs1572788T4C and HOMA-IR or the 2 h oral glucose tolerance test.
Decreased HDL-cholesterol and increased triglycerides were observed for each rs1572788 C-allele in the Genome-Wide Associations Scans for Total Cholesterol, HDL-C, LDL-C and triglycerides (n = 96,908, β = − 0.008, P = 0.013 and n = 93,562, β = 0.009, P = 0.004, respectively). We observed non-significant associations for rs1572788T4C with total and LDL-cholesterol, as well as with obesity traits studied in the GIANT study, however, the direction of the effect is consistent with increased blood lipids and obesity with each rs1572788 C-allele (Supplementary Table 5 ).
DISCUSSION
The transcriptional co-activator (CRTC) family is implicated with energy expenditure (CRTC1 and CRTC3) 37, 38 and glucose metabolism (CRTC2) 16 in animal models. In the present study, we aimed to study the effect of CRTC2 SNPs on the development of diabetes in SOT recipients, a population at high risk of developing metabolic abnormalities, and in population-based samples. We also extended our analyses to investigate obesity and other metabolic traits. The CRTC2 rs8450-AA genotype was associated with increased risk of NODAT, increased FBG, and BMI in a sample of 156 patients with SOT. Results on NODAT were replicated only in the second STCS replication sample (n = 438), while in the first and the combined STCS replication samples, the SNP only showed significant influence in the population at higher risk of developing NODAT, mainly in recipients having received a graft from a deceased donor and treated with TAC. We also observed a significant association for BMI in the STCS replication sample; overweight and obesity were also more frequent in patients carrying the rs8450-AA genotype at 12 months post SOT. CRTC2 rs8450G4A was also associated with increased risk of new-onset hyperlipidemia following SOT and with lower HDL-cholesterol blood levels. Furthermore, we also found the increased risk of the C-allele of rs1572788 (in complete linkage disequilibrium with rs8450 A-allele) on diabetic and lipidemic traits in two large population-based samples (MAGIC and GWAS for total cholesterol, HDL-C, LDL-C and triglycerides, respectively), and a consistent direction even though non-significant between rs1572788T4C and obesity traits in the GIANT study.
CRTC2 rs8450G4A was associated with NODAT in the total discovery sample and only in the second STCS replication sample, but not in the total STCS sample in which a significant association was observed only in the subgroup of patients at higher risk of developing NODAT. This could partly be explained by the difference of NODAT diagnostic criteria, which is only based on anti-diabetic treatment in the first STCS replication sample. Another explanation could be the high percentage of patients receiving an organ from a living donor in the first STCS replication sample (28%, Supplementary Table 2) compared with only 11.5% in the discovery sample (Supplementary Table 1 ). Deceased donor is a common risk factor of NODAT 11 and the impact of the SNP seems to be more prominent in the groups at higher risk of developing MetS traits. In addition, when differentiating kidney and non-kidney transplant recipients (Table 3) we observed a significant association between the CRTC2 rs8450-AA genotype and NODAT in non-kidney transplant recipients. The percentage of non-kidney transplant recipients was higher in the second STCS replication sample compared with the first STCS sample (Supplementary Table 2 ) and it should be noted that kidney transplant recipients had higher percentages of living donors compared with non-kidney transplant recipients (43% versus 2%, respectively). Moreover, kidney transplant recipients usually have obesity and other metabolic problems already before transplantation compared with other solid organ recipients, which could explain the differential effect of the SNP depending on the type of the transplanted organ. Interestingly, in both the discovery and the combined STCS samples, the effect of the SNP was stronger in NODAT cases developed after the first year post SOT (data not shown), It maybe that the effect of the CRTC2 SNP on NODAT is more important in the long term, but this remains to be further studied.
In the GWAS literature, CRTC2 SNPs were not found to be associated with diabetes, obesity or hyperlipidemia. On the other hand, by testing the individual effect of CRTC2 rs1572788T4C SNP on diabetic and lipidemic traits in two population-based samples, a significant effect was observed, even though this effect is very weak and the variance explained by the SNP is very small (Supplementary Table 5 ) and could thus not be detected by GWAS. However, patients with SOT is a population at risk of developing MetS traits, because of the disease itself and/or the immunosuppressive medications, both can act as an important trigger, unmasking different genetic factors. So in this at risk population, the effect of CRTC2 SNP was more pronounced, even in much smaller sample sizes compared with population-based samples. In addition, in the GWAS of NODAT, 14 CRTC2 SNPs did not reach genome-wide level of significance. Moreover, most of the SNPs retained in this GWAS were not replicated in another study with NODAT. 15 In fact, both GWAS and candidate gene studies are important gene association approaches and both are subject to the same artifacts of spurious association findings. Depending on the methodology of these studies (sample size, definition of the phenotypes, MAF of the SNPs and corrections for multiple testing, and so on), discordances between both approaches could be seen. GWAS relies on indirect association to locate a disease-causing variant while candidate gene approach relies on an a priori hypothesis to identify this disease-causing variant. For all of these reasons, replication of positive finding in either approach is of utmost importance to validate the results.
The functional activity of this SNP, in the regulatory three prime untranslated region (3'-UTR), is unknown and data from 1000 Genomes 39 showed that 78 SNPs in the CRTC2 gene region are in high linkage disequilibrium (r 2 threshold ⩾ 0.8) with rs8450G4A. We used the RegulomeDB database that annotates SNPs with known and predicted regulatory elements in the intergenic regions of the Homo sapiens genome. 40 This database reveals known and predicted regulatory DNA elements including regions of DNAase hypersensitivity, binding sites of transcription factors and promoter regions that have been biochemically characterized to regulation transcription. Source of these data include public data sets from GEO, the ENCODE project and published literature. Regarding CRTC2 rs8450G4A, several of these proxy SNPs (for example, rs6680140 with r 2 = 1) show cis-eQTL effect on the expression of CRTC2 and fall into the autoimmune regulatory motif, influence the binding of several proteins (JUN, CREBBP and ELF1), and has several histone marks (H3k09me3, H4k20me1, and so on). Altogether, these data suggest that the SNP might have a regulatory function.
Interestingly, among the analyzed clinical factors, treatment with corticosteroids was not associated with NODAT, neither in the discovery cohort nor in the STCS sample. However, in our samples most of the patients were treated with corticosteroids so it is difficult to draw major conclusions. On the other hand, the cumulative corticosteroids dosages and the duration of therapy rather than the simple corticosteroids administration could be the most influencing factors. In our discovery sample, the cumulative dosages of corticosteroids at the first year post transplantation were not associated with NODAT outcome. In the literature, several studies did not find any influence of cumulative corticosteroid dosages on the appearance of NODAT. [41] [42] [43] [44] [45] The current lower dosages of corticosteroids used in different immunosuppressive regimens could contribute to the negative association with NODAT appearance in our study.
This study has several limitations and strengths. Random and FBG levels were only available in the second STCS replication sample and the diagnosis of NODAT in the first STCS replication sample was only based on anti-diabetic treatments post SOT. The genotype of the rs8450G4A SNP of the liver transplant donors is unknown, therefore the significant effect of the SNP on NODAT found in non-kidney transplant recipients, in which nearly half of them are liver transplant recipients, should be interpreted with caution. However, CRTC2 is expressed in different tissues and is implicated in glucose regulation through different mechanisms (gluconeogenesis, insulin signaling and beta-cell survival 16, 19, 22 ), which could highlight the importance of recipient CRTC2 genotype even in liver transplant recipients. In addition, by excluding patients with liver transplantation from the non-kidney transplant recipients' analyses, a significant association between the CRTC2 SNP and NODAT is still observed (data not shown). The present results do not allow the determination of whether the rs8450G4A SNP is the causative variant or merely a proxy of one or more yet unidentified variants. Despite the possible regulatory functions proposed by the RegulomeDB database, further studies are needed to elucidate, which precise mechanisms underlie the observed association. This study included people of Caucasian origin and results cannot be generalized to other ethnic groups. On the other hand, the fact that the results were replicated in two independent samples with SOT and in large population-based samples, the latter used as a proof of concept of the effect of the polymorphism, strengthens the validity of our data.
In conclusion, our results suggest that variations in CRTC2 have an important role in the high prevalence of MetS complications observed in patients with SOT. Besides, by studying CRTC2 SNPs in population-based samples, we still observed a weak yet significant association, thereby suggesting that the effect of CRTC2 variations is more important in population at risk of developing different MetS traits than in the general population. This is the first study showing the importance of CRTC2 variations with NODAT and other MetS traits in patients with SOT. The assessment of the major risk gene variants would allow predicting vulnerability for developing Mets phenotypes and thus adapt the immunosuppressive treatment from the beginning by genotyping the patients before transplantation. In the long term, these patients could benefit from individualized immunosuppressive regimens adapted to their genetics and environment.
